Savara
NASDAQ: SVRAAustin, US · Founded 2007 · Delaware corporation · 125 employees on LinkedIn · 6 known investors
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.
Founders & leadership
Investors · 6
Reported raises · per SEC filings
Form D private placements$30.9M disclosed across 2 rounds · 2014–2019
▶$26.8MraisedJan 2020 · 18 investors · PharmaceuticalsRule 506(b)
- Richard J. HawkinsDirector
- An van Es-JohanssonDirector
- Ricky SunDirector
- Taneli JouhikainenExecutive Officer
- Mike CieslaExecutive Officer
- Badrul ChowdhuryExecutive Officer
- John LordExecutive Officer
- Peter GinsburgExecutive Officer
- Kate McCabeExecutive Officer
- Nevan ElamDirector
- Joseph S. McCrackenDirector
- Matthew PaulsDirector
- David A. RamsayDirector
- Robert NevilleExecutive Officer, Director
- David L. LowranceExecutive Officer
- Offering amount
- $75M
- Amount sold
- $26.8M
- Sales commissions
- $1.4M
- Placement agents
- Evercore Group L.L.C., Jefferies LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedMar 2014 · 2 investors · PharmaceuticalsRule 506(b)
- Lewis ShusterDirector
- David A. RamsayDirector
- Santosh J. VetticadenExecutive Officer
- Gregory D. GorgasExecutive Officer
- Patrick KeranExecutive Officer
- Jack LiefDirector
- Brandi L. RobertsExecutive Officer
- R. Martin EmanueleExecutive Officer
- Brian M. CulleyExecutive Officer, Director
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Savara for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $190.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $149.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $184.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Savara do?
- Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases. The company focuses on novel therapeutic approaches for patients with rare respiratory conditions.
- Who are Savara's investors?
- Savara's investors include Bain Capital Life Sciences, Central Texas Angel Network, Green Park & Golf Ventures, Keiretsu Forum, Moore Venture Partners, New Enterprise Associates (NEA).
- How much funding has Savara raised?
- Savara has disclosed $30.9M raised across 2 rounds.
- Where is Savara headquartered?
- Savara is headquartered in Austin, US.